Lb Pharmaceuticals
Neurology & CNS Therapeutics
Salary insights
Compensation ranges based on this company's open jobs
Median
$390k
Typical range
$390k
Open positions
1
1
Jobs
Architect
100%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Architect | 1 | $390k | $390k |
Highest paying role
Deputy General Counsel / Vice President, Healthcare Law & Compliance
$390k
Normalized to USD per year
Growth
Hiring Momentum
28/100
Slowing
Open positions
1
0 opened / 0 closed in 30 days
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Legal
100% ▲
Financials
Total raised
$140.9M
Latest round
Venture - Series Unknown
Funding rounds
8
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2023 | $110.7M | Details |
| Debt Financing | 2022 | $16.6M | Details |
| Venture - Series Unknown | 2022 | $903k | Details |
| Debt Financing | 2020 | $4.6M | Details |
| Venture - Series Unknown | 2018 | $6.3M | Details |
| Venture - Series Unknown | 2018 | $330k | Details |
| Venture - Series Unknown | 2017 | $462k | Details |
| Venture - Series Unknown | 2016 | $969k | Details |
People
Zachary Prensky
Executive Officer, Director
Marc Panoff
Executive Officer
Anna Eramo
Executive Officer
Andrew Vaino
Executive Officer
Robert Ruffolo
Director
Rebecca Luse
Director
Rajul Jain
Director
Ran Nussbaum
Director
Chen Yu
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
PontifaxVia a fund
55 portfolio companies: Climb Bio, CadenSee, Crystalys Therapeutics - Passionate. Dedicated. We improve lives. and 52 more
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
LB Pharmaceuticals to Participate in Upcoming September Investor Events
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (
Read more
Report
LB Pharmaceuticals Reports Q2 2026 Results, Advances LB-102 Timeline and Pipeline Expansion LBRX Stock News
LB Pharmaceuticals accelerated data readout for LB-102 in schizophrenia to 2027 and plans expansion into other neuropsychiatric indications.Quiver AI SummaryLB Pharmaceuticals Inc. has announced an accelerated timeline for the topline data readout from it
Read more
Report
LB Pharmaceuticals Inc (LBRX) stock price, news, quote and history - Yahoo Finance
Find the latest LB Pharmaceuticals Inc (LBRX) stock quote, history, news and other vital information to help you with your stock trading and investing.
Read more
Report
LB Pharmaceuticals Inc (LBRX) Stock Price, News, Quote & History - Yahoo Finance
Find the latest LB Pharmaceuticals Inc (LBRX) stock quote, history, news and other vital information to help you with your stock trading and investing.
Read more
Report
LB Pharmaceuticals Inc (LBRX) stock price, news, quote and history - Yahoo Finance
Find the latest LB Pharmaceuticals Inc (LBRX) stock quote, history, news and other vital information to help you with your stock trading and investing.
Read more
Report
LB Pharmaceuticals Announces Pricing of its Upsized Initial Public Offering
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (
Read more
Report
LB Pharmaceuticals Announces Positive Topline Results from Phase 2 Trial of LB-102 in Schizophrenia
Robust 359 patient trial met primary endpoint with statistically significant reduction in PANSS total score at all dose levels compared to placebo ...
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
New York
United States
HQ
200-500 est. staff